Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
[HTML][HTML] The landscape of alpha fetoprotein in hepatocellular carcinoma: where are we?
X Hu, R Chen, Q Wei, X Xu - International journal of biological …, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and has been
acknowledged as a leading cause of death among cirrhosis patients. Difficulties in early …
acknowledged as a leading cause of death among cirrhosis patients. Difficulties in early …
Icaritin exacerbates mitophagy and synergizes with doxorubicin to induce immunogenic cell death in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) resistant to both chemotherapy and immunotherapy is
among the deadliest malignancies. Doxorubicin widely used in transarterial chemotherapy …
among the deadliest malignancies. Doxorubicin widely used in transarterial chemotherapy …
[HTML][HTML] Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
FH Kong, QF Ye, XY Miao, X Liu, SQ Huang, L **ong… - Theranostics, 2021 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common type of liver cancer and one of the
leading causes of cancer-related death worldwide. Advanced HCC displays strong …
leading causes of cancer-related death worldwide. Advanced HCC displays strong …
CXCR2 inhibition enables NASH-HCC immunotherapy
Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic
steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data …
steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data …
Blocking CD47 promotes antitumour immunity through CD103+ dendritic cell–NK cell axis in murine hepatocellular carcinoma model
S Wang, Q Wu, T Chen, R Su, C Pan, J Qian… - Journal of …, 2022 - Elsevier
Background & Aims The CD47–signal regulatory protein α (SIRPα) axis inhibits dendritic cell
(DC) phagocytosis and contributes to immune evasion. However, the behaviour of DCs and …
(DC) phagocytosis and contributes to immune evasion. However, the behaviour of DCs and …
[HTML][HTML] Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
Background Modulation of adaptive immunity may underscore the efficacy of trans-arterial
chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by …
chemoembolization (TACE). We evaluated the influence of TACE on T-cell function by …
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
BACKGROUND MEK inhibitors have limited activity in biliary tract cancers (BTCs) as
monotherapy but are hypothesized to enhance responses to programmed death ligand 1 …
monotherapy but are hypothesized to enhance responses to programmed death ligand 1 …
Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival
Immune-checkpoint therapy has failed to demonstrate meaningful clinical benefit in
unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known …
unselected cases of pancreatic adenocarcinoma (PDAC), but a subset of PDACs are known …
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
BP Keenan, L Fong, RK Kelley - Journal for immunotherapy of cancer, 2019 - Springer
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …
confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors …